Physician profile
Mitchell D Martin
NPI 1639179708
$23,235.93
in general payments reported to CMS, 2019-2025
69 companies · $3,487 in 2025
The $3,487 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,230 · 2020: $2,738 · 2021: $4,562 · 2022: $2,787 · 2023: $3,196 · 2024: $3,236 · 2025: $3,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,863 · Education: $57.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,862.74 |
| Education | $57.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,021.17 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Genentech USA, INC. | $1,618.10 | 2019-2025 | Phesgo, Lunsumio, Polivy |
| Abbvie INC. | $1,548.80 | 2019-2025 | |
| Amgen INC. | $1,429.67 | 2019-2023 | Kyprolis, Xgeva, Vectibix |
| Janssen Biotech, INC. | $1,175.96 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Seagen INC. | $1,114.06 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Merck Sharp & Dohme LLC | $1,036.05 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $963.85 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Celgene Corporation | $947.28 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Genzyme Corporation | $911.09 | 2019-2025 | |
| Pfizer INC. | $771.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $767.27 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Novartis Pharmaceuticals Corporation | $753.08 | 2019-2025 | |
| Incyte Corporation | $623.58 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $562.08 | 2019-2025 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.